ArticleAging2022
M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine.
Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy.International journal of nanomedicine · 2026Review
- Constructing a bladder cancer prognostic model related to exosome using machine learning and identifying THBS1 as a potential target.Cancer cell international · 2025Article
- Macrophage-derived exosomes in cancer: a double-edged sword with therapeutic potential.Journal of nanobiotechnology · 2025Review
- Nicotine promotes M2 macrophage polarization through α5-nAChR/SOX2/CSF-1 axis in lung adenocarcinoma.Cancer immunology, immunotherapy : CII · 2024Article
- Review
- The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Macrophage-derived extracellular vesicles as new players in chronic non-communicable diseases.Frontiers in immunology · 2024Review
- Bladder Cancer in Exosomal Perspective: Unraveling New Regulatory Mechanisms.International journal of nanomedicine · 2024Review
- A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer.European journal of medical research · 2023Article
- Phytochemicals and Cancer Treatment: Cell-Derived and Biomimetic Vesicles as Promising Carriers.Pharmaceutics · 2023Review
- Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy.Pharmaceutics · 2023Article
- The Potential Use of Exosomes in Anti-Cancer Effect Induced by Polarized Macrophages.Pharmaceutics · 2023Review
- The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gemcitabine (GEM) is one of the first choice drugs for treating bladder cancer. In this study, we loaded M1 macrophage-derived exosomes (M1-Exo) with GEM by ultrasonication technique to derive an M1-Exo-GEM drug delivery system, and then explored its effects on bladder cancer. After inducing M1 polarization of macrophages
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.